Literature DB >> 6430441

Tamoxifen and liver damage.

A M Blackburn, S A Amiel, R R Millis, R D Rubens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6430441      PMCID： PMC1442108          DOI： 10.1136/bmj.289.6440.288

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels.

Authors:  H W Ward
Journal:  Br Med J       Date:  1973-01-06

2.  Safety of tamoxifen.

Authors:  J S Patterson; M Baum
Journal:  Lancet       Date:  1978-01-14       Impact factor: 79.321

3.  Bone 'flare,' hypercalcemia, and jaundice after tamoxifen therapy.

Authors:  B L Agrawal; L Zelkowitz
Journal:  Arch Intern Med       Date:  1981-08
  3 in total
  10 in total

Review 1.  Tamoxifen in postmenopausal women a safety perspective.

Authors:  E Robinson; G G Kimmick; H B Muss
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 2.  Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?

Authors:  M O'Brien; T J Powles
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

3.  Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice.

Authors:  Pirunthan Perampalam; Haider M Hassan; Grace E Lilly; Daniel T Passos; Joseph Torchia; Patti K Kiser; Andrea Bozovic; Vathany Kulasingam; Frederick A Dick
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

Review 4.  Drug-induced cholestasis.

Authors:  H J Zimmerman; J H Lewis
Journal:  Med Toxicol       Date:  1987 Mar-Apr

5.  A case-control study of non-alcoholic fatty liver disease in breast cancer.

Authors:  Ahmet Bilici; Mustafa Ozguroglu; Ismail Mihmanli; Hande Turna; Ibrahim Adaletli
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

6.  Phase I trial of droloxifene in patients with metastatic breast cancer.

Authors:  A U Buzdar; S Kau; G N Hortobagyi; R L Theriault; D Booser; F A Holmes; R Walters; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.

Authors:  S Maruyama; C Hirayama; J Abe; J Tanaka; K Matsui
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

8.  Effect of toremifene on antipyrine elimination in the isolated perfused rat liver.

Authors:  L K Webster; A G Ellis; J F Bishop
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

10.  A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.

Authors:  L Kangas; A L Nieminen; G Blanco; M Grönroos; S Kallio; A Karjalainen; M Perilä; M Södervall; R Toivola
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.